Emcure 在印度推出仿制 Wegovy，以改善肥胖问题上升期间减肥治疗的可及性。 Emcure launches generic Wegovy in India to improve access to weight-loss treatment amid rising obesity.

Emcure Petrogines在印度推出新Nordisk减重药品Wegovy的通用版本Poviztra。 Emcure Pharmaceuticals has launched Poviztra, a generic version of Novo Nordisk’s weight-loss drug Wegovy, in India. 以五种剂量提供每星期一次的微硫化物注射,被批准用于对肥胖或超重且与体重有关条件的成年人进行长期体重管理,并降低心血管风险。 The once-weekly semaglutide injection, available in five dosages, is approved for chronic weight management in adults with obesity or overweight with weight-related conditions, and to reduce cardiovascular risk. 该项目月价为₹8,790，旨在改善印度日益严重的肥胖危机，影响超过2.54亿成年人。 Priced from ₹8,790 per month, it aims to improve access amid India’s rising obesity crisis, affecting over 254 million adults. 发射标志着Emcure进入了日益增长的代谢性疾病市场,计划通过许可证发放和研发来扩大其投资组合。 The launch marks Emcure’s entry into the growing metabolic disease market, with plans to expand its portfolio through in-licensing and R&D.